Navigation Links
Phase III Studies of EXPAREL(TM) (DepoBupivacaine) from Pacira Complete Enrollment
Date:1/6/2009

PARSIPPANY, N.J., Jan. 6 /PRNewswire/ -- Pacira Pharmaceuticals, Inc., an acute care specialty pharmaceutical company, announced today that enrollment has been completed in two pivotal Phase III SIMPLE trials to evaluate the safety and efficacy of a single intraoperative administration of EXPAREL(TM) (DepoBupivacaine) for prolonged postoperative analgesia.

Results from the studies in hemorrhoidectomy and in total knee arthroplasty (TKA) are expected to provide the primary clinical data, in addition to extensive existing preclinical and clinical data, for a planned 2009 NDA filing under U.S. Food and Drug Administration 505 (b)(2) regulations.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070618/PACIRALOGO)

EXPAREL, a proprietary product from Pacira Pharmaceuticals, is a novel long-acting, sustained-release formulation of bupivacaine, a local anesthetic widely used for treating postoperative pain. EXPAREL is being studied in several different types of surgical procedures where postoperative pain management is especially problematic and where the need for prolonged analgesia with a single intraoperative administration can provide a significant improvement in pain relief -- especially during the first 72-hours following surgery -- while also minimizing the need for opioids. With improved prolonged postoperative pain management and a reduction in opioid consumption, Pacira believes patients treated with EXPAREL will experience better pain management and have fewer opioid-related side effects such as nausea and vomiting, and improved outcomes overall.

Recently, Pacira reported the results of a Phase II TKA study of EXPAREL at the International College of Surgeons meeting in Vienna, Austria. The data showed the new sustained-release analgesic significantly reduced postoperative pain, opioid
'/>"/>

SOURCE Pacira Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... , July 10, 2014  Valeant Pharmaceuticals International, ... today announced it has completed the sale to Galderma ... Dysport owned or held by Valeant for $1.4 billion ... Nestle S.A, which recently completed its acquisition of Galderma. ... divestiture of our products to a company that is ...
(Date:7/10/2014)... July 10, 2014  Decision Resources Group finds ... disease (ID) specialists are willing to prescribe Durata,s ... for use as OPAT, approximately two-thirds of the ... to their hospital inpatients. However, our findings indicate ... are initiated on OPAT following hospital discharge, and ...
(Date:7/10/2014)... -- CVS Caremark Corporation (NYSE: CVS ) today ... dividend of $0.275 (27.5 cents) per share on the corporation,s ... to holders of record on July 21, 2014. ... to helping people on their path to better health as ... States . Through the company,s more than 7,600 CVS/pharmacy ...
Breaking Medicine Technology:Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3
(Date:7/11/2014)... 11, 2014 Alliance for Cancer ... non-profit dedicated exclusively to cell and gene therapies ... has joined the organization as Senior Development Officer. ... deep experience securing gifts and addressing influential donors. ... Giving Director for NewYork Presbyterian Hospital/Columbia University Medical ...
(Date:7/11/2014)... 2014 Global enterprises today are shifting ... day-to-day management activities. Managed services offer these global enterprises ... economic slowdown resulted into rising operational costs to companies. ... considered to be the global market driver for expanding ... global managed services market is estimated to grow from ...
(Date:7/11/2014)... July 11, 2014 Presently, disposable medical ... healthcare equipment and supplies segment. During the past two ... steady growth (on an average 12.5% per year), primarily ... settings. Currently, the US is the largest market for ... share of 40%. The second position is held by ...
(Date:7/11/2014)... Researchers from The Miriam Hospital have found that ... significantly higher rates of smoking than those without ... less likely to attempt quitting than those without ... be sufficient for this population. The study and ... print in the American Journal of Public ...
(Date:7/11/2014)... has found that organic foods and crops have ... including more antioxidants and fewer, less frequent pesticide ... 343 peer-reviewed publications comparing the nutritional quality and ... fruits, vegetables, and grains. The study team applied ... and non-organic foods. , "Science marches on," ...
Breaking Medicine News(10 mins):Health News:Alliance for Cancer Gene Therapy (ACGT) Welcomes Joshua Corday as Senior Development Officer 2Health News:Alliance for Cancer Gene Therapy (ACGT) Welcomes Joshua Corday as Senior Development Officer 3Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 4Health News:Global Disposable Medical Supplies Market to See Robust Growth Through Next Decade, According to New TriMark Report Available at MarketPublishers.com 2Health News:Global Disposable Medical Supplies Market to See Robust Growth Through Next Decade, According to New TriMark Report Available at MarketPublishers.com 3Health News:Miriam Hospital study examines smoking prevalence 2Health News:Major study documents nutritional and food safety benefits of organic farming 2Health News:Major study documents nutritional and food safety benefits of organic farming 3
... Enjoy the Freedom to Breathe, Event to Raise Awareness of Benefits ... ... Hundreds of attendees,of this week,s 2007 National Conference on Tobacco or ... Thursday outside,the Minneapolis Convention Center to raise awareness about the benefits ...
... Open Access: freely available for anyone to read, ... the authorship is properly attributed. , This week ... that aim to highlight the profound influence of ... of Science Editors Global Theme Issue on Poverty ...
... Care Pipeline Offers State-of-the-art Treatment, MEMPHIS, ... leader in cancer care, announced today the ... square foot, state-of-the art,facility is being opened ... provide ,western-style, comprehensive cancer care. Shanghai,represents the ...
... of gloss, depth of image, and ... MANSFIELD, Texas, Oct. 22 Solvay Engineered Polymers,Inc., ... use in the,production of extruded sheet. The new ... acrylic layer onto a substrate of thermoplastic,polyolefin (TPO) ...
... and NEW YORK, Oct. 22 ,Genzyme Corporation (Nasdaq: ... BIVN ),announced this afternoon that Bioenvision stockholders have ... Genzyme at a reconvened special,shareholder meeting in New ... have now ceased trading and the company will,be ...
... ,Super Bug, Other Biological ... ... dozens of cases of MRSA,the drug-resistant staph bacterium, are being reported ... student, some,school districts are taking the proactive step of bringing in ...
Cached Medicine News:Health News:Hundreds to Gather for Rally in Celebration of Right to Breathe Clean Air 2Health News:Which intervention would do the most to improve the health of the extreme poor? 2Health News:Which intervention would do the most to improve the health of the extreme poor? 3Health News:Which intervention would do the most to improve the health of the extreme poor? 4Health News:Which intervention would do the most to improve the health of the extreme poor? 5Health News:West Clinic Continues Expansion Into Asian Market With Opening of Shanghai Cancer Center 2Health News:New ADDHERE(TM) Adhesive Tie Layer Bonds Acrylic Cap Layers to Substrates of Thermoplastic Polyolefin (TPO) in Production of Sheet for Use in Thermoforming 2Health News:New ADDHERE(TM) Adhesive Tie Layer Bonds Acrylic Cap Layers to Substrates of Thermoplastic Polyolefin (TPO) in Production of Sheet for Use in Thermoforming 3Health News:New ADDHERE(TM) Adhesive Tie Layer Bonds Acrylic Cap Layers to Substrates of Thermoplastic Polyolefin (TPO) in Production of Sheet for Use in Thermoforming 4Health News:Bioenvision Shareholders Approve Acquisition by Genzyme Corporation 2Health News:Bioenvision Shareholders Approve Acquisition by Genzyme Corporation 3Health News:Bioenvision Shareholders Approve Acquisition by Genzyme Corporation 4Health News:MARCOR Responds to Deadly MRSA Outbreak 2
Curved shafts with micro Pierse type tips. Flat open serrated handle with dull finish....
Straight shafts with 0.1 mm Pierse tips. Flat smooth handle with dull finish....
Colibri style 0.1 mm Pierse tips. Flat smooth handle with dull finish....
The Elschnig teeth of this forceps are ideal for grasping sclera during suturing. Delicate tying platform handles the finest suture material. 0.12 mm, 1 x 2 teeth....
Medicine Products: